We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) (MITCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02307149
Recruitment Status : Recruiting
First Posted : December 4, 2014
Last Update Posted : January 12, 2018
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Open label, single arm study of intratumoral CVA21 and ipilimumab in advanced melanoma patients.

Condition or disease Intervention/treatment Phase
Melanoma Biological: CAVATAK Drug: Ipilimumab Phase 1

Detailed Description:

Primary Objective:

To evaluate the safety and efficacy of CAVATAK (CVA21) administered intratumorally in combination with the approved dose and schedule of ipilimumab. Of particular interest is to estimate the overall response rate (ORR) in the subgroup of subjects with unresectable or metastatic stage III B/C or IV melanoma who have progressed on a single prior anti-PD-1 therapy.

Secondary Objectives:

  1. Assess the clinical efficacy of ipilimumab in combination with intratumoral CVA21 in terms of:

    • Immune-related progression-free survival (irPFS) at 6 and 12 months,
    • Durable response rate (DRR),
    • 1-year survival,
    • Overall survival (OS), and
    • Quality of life.
  2. Assess the response of injected and non-injected melanoma lesions after CVA21 and ipilimumab.
  3. Assess the time to initial response.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 59 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
Study Start Date : February 2015
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
Drug Information available for: Ipilimumab
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: CAVATAK and ipilimumab
CAVATAK intratumoral injection up to a total dose of 3 x 10⁸ TCID50 and ipilimumab intravenously at the recommended dose of 3 mg/kg
Biological: CAVATAK
CAVATAK is a preparation of CVA21
Other Name: Coxsackievirus A21, CVA21
Drug: Ipilimumab
Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma
Other Name: Yervoy®


Outcome Measures

Primary Outcome Measures :
  1. Response [ Time Frame: 106 days ]
    Best response of complete response (CR) or partial response (PR)


Secondary Outcome Measures :
  1. DRR [ Time Frame: lasting 26 weeks or longer ]
    Durable Response Rate

  2. PFS [ Time Frame: At 6 and 12 months ]
    Progression-Free Survival

  3. OS [ Time Frame: Through study completion, an average of 2 years ]
    Overall


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with unresectable or metastatic stage III B/C or IV melanoma. Patients enrolled under this version of the protocol must also have progressed on prior anti-PD-1 therapy, according to RECIST 1.1 criteria. Patients who progressed within 3 months of treatment start are excluded.
  2. Patients must have at least one cutaneous or subcutaneous tumor, measuring 0.5 to 5.0 cm in the longest diameter, or a palpable lymph node. At least one tumor must qualify as an index lesion that can be accurately and reproducibly measured in two dimensions for which the longest diameter is .10 mm (.15 mm in short axis diameter [SAD] for lymph nodes), and be amenable to intratumoral injection.
  3. Histological confirmation of melanoma will be required by previous biopsy or cytology.
  4. Patients who have received prior ipilimumab treatment for metastatic melanoma are not eligible.
  5. Patients with ≤ 3 visceral metastases (excluding pulmonary lesions), with no lesions >3.0 cm. Patients with substantial tumor burden of non-measurable disease may not be good candidates for an immunotherapy and should be discussed with the Medical Monitor.

7. ECOG performance status of 0-1.

Key Exclusion Criteria:

  1. Patients with tumors to be injected lying close to an airway, major blood vessel or spinal cord that, in the opinion of the Investigator, could cause occlusion or compression in the case of tumor swelling or erosion into a major vessel in the case of necrosis. Patients with lesions in mucosal areas (vulvar, anus, oral cavity, etc.), are eligible, as long as the subject has at least one lesion suitable for injection; consult Medical Monitor for confirmation.
  2. Patients with active, known or suspected autoimmune disease except for autoimmune thyroiditis or vitiligo. Thyroiditis patients must be asymptomatic, on adequate thyroid replacement and have normal thyroid function tests.
  3. Patients with active colitis or immune-mediated colitis that has not resolved to grade 1 or less.
  4. Patients with untreated brain metastases. Patients with treated brain metastases who are off corticosteroids for at least two weeks and who demonstrate control of brain metastases with follow-up imaging 4 or more weeks after initial therapy are eligible.
  5. Patients previously treated with CVA21.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02307149


Contacts
Contact: Leslie Guerreiro leslie.guerreiro@viralytics.com

Locations
United States, California
City of Hope National Medical Center, Recruiting
Duarte, California, United States, 91010
Contact: Ashley Williams    626-218-0572      
Principal Investigator: Kim Margolin, MD         
UC San Diego Moores Cancer Center Recruiting
La Jolla, California, United States, 92093
Contact: Hailey Tipton    858-822-0201      
Principal Investigator: Gregory Daniels, MD, PhD         
John Wayne Cancer Institute Recruiting
Santa Monica, California, United States, 90404
Contact: Kelly Garver    310-582-7456      
Principal Investigator: Steven O'Day, MD         
United States, Florida
Sylvester Comprehensive Cancer Center Recruiting
Miami, Florida, United States, 33136
Contact: Juan Salvador    305-243-7358      
Principal Investigator: Lynn Feun, MD         
United States, Illinois
Advocate Health, SC Recruiting
Park Ridge, Illinois, United States, 60068
Contact: Kathy Tolzien    847-410-0658      
Principal Investigator: Jon Richards, MD         
United States, Massachusetts
Massachusetts General Hospital Not yet recruiting
Boston, Massachusetts, United States, 02114
Contact: Rosemary Boyle    617-724-3173      
Principal Investigator: Ryan Sullivan, MD         
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Jennifer Maattala    617-632-3992      
Principal Investigator: Ryan Sullivan, MD         
United States, New Jersey
Atlantic Melanoma Center Recruiting
Morristown, New Jersey, United States, 07960
Contact: Maureen Nowakowski    973-971-6298      
Principal Investigator: Eric Whitman, MD         
United States, Oregon
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: Chris Fountain    503-215-2691      
Principal Investigator: Brendan D Curti, MD         
United States, Utah
Huntsman Cancer Institute Recruiting
Salt Lake City, Utah, United States, 84112
Contact: Tamara Willis    801-587-4767      
Principal Investigator: Robert Andtbacka, MD         
Sponsors and Collaborators
Viralytics
Providence Health & Services
Investigators
Principal Investigator: Brendan Curti, MD Providence Health & Services
More Information

Responsible Party: Viralytics
ClinicalTrials.gov Identifier: NCT02307149     History of Changes
Other Study ID Numbers: VLA-013
PHS IRB: 14-241 ( Other Identifier: Providence Health & Services )
First Posted: December 4, 2014    Key Record Dates
Last Update Posted: January 12, 2018
Last Verified: January 2018

Keywords provided by Viralytics:
melanoma
ipilimumab
coxsackievirus A21
CAVATAK
CVA21
checkpoint inhibitors

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs